ResearcherNorthwestern UniversityActive in the last 2 years

Tarık Demir

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6334-4079; OpenAlex author ID A5004333469. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 6

Papers, trials and grants by year

2025: 1 paper · 2026: 1 paper

Papers 2

KRAS Subtype Modifies Outcomes with Immunomodulatory Therapy in Advanced Pancreatic Ductal Adenocarcinoma: Evidence from Early-Phase Trials. Co-author DOI 10.3390/cancers18132037 ↗
Threading the Needle: Navigating Novel Immunotherapeutics in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers17050715 ↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Devalingam Mahalingam · 2 shared papers, 2025–2026 · strength 0.71
- Paper Threading the Needle: Navigating Novel Immunotherapeutics in Pancreatic Ductal Adenocarcinoma. DOI 10.3390/cancers17050715 ↗
- Paper KRAS Subtype Modifies Outcomes with Immunomodulatory Therapy in Advanced Pancreatic Ductal Adenocarcinoma: Evidence fro… DOI 10.3390/cancers18132037 ↗
Dılşa Mızrak Kaya · 1 shared paper, 2026 · strength 0.29
- Paper KRAS Subtype Modifies Outcomes with Immunomodulatory Therapy in Advanced Pancreatic Ductal Adenocarcinoma: Evidence fro… DOI 10.3390/cancers18132037 ↗
Sheetal Mehta Kircher · 1 shared paper, 2026 · strength 0.29
- Paper KRAS Subtype Modifies Outcomes with Immunomodulatory Therapy in Advanced Pancreatic Ductal Adenocarcinoma: Evidence fro… DOI 10.3390/cancers18132037 ↗
Aparna Kalyan · 1 shared paper, 2026 · strength 0.29
- Paper KRAS Subtype Modifies Outcomes with Immunomodulatory Therapy in Advanced Pancreatic Ductal Adenocarcinoma: Evidence fro… DOI 10.3390/cancers18132037 ↗
Al B. Benson · 1 shared paper, 2026 · strength 0.29
- Paper KRAS Subtype Modifies Outcomes with Immunomodulatory Therapy in Advanced Pancreatic Ductal Adenocarcinoma: Evidence fro… DOI 10.3390/cancers18132037 ↗
Mary F. Mulcahy · 1 shared paper, 2026 · strength 0.29
- Paper KRAS Subtype Modifies Outcomes with Immunomodulatory Therapy in Advanced Pancreatic Ductal Adenocarcinoma: Evidence fro… DOI 10.3390/cancers18132037 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.